System solution for syringes, vials and cartridges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

 

Optima Pharma has, in the form of the INOVA SV, a well proven machine that had been re-engineered in recent years into a highly flexible modular system.

The INOVA SV allows the processing of nested ready to use syringes, of nested vials and cartridges in one unit. Customers make a quick change within 30 minutes. The contact points of the system to the containers are reduced to an absolute minimum to allow for gentler processing. In addition, there is no glass to glass contact of any kind during the processing. A further factor concerns the filling systems. A number of variations are possible, all of which can be set up very quickly as part of the format change work: Rotary piston pumps, peristaltic pumps, mass flow metering and time-pressure systems offer advantages relative to the various types of pharmaceuticals. Additional modules and functions can be integrated, including filling under vacuum, pre- and post-flushing with gas, and up to 100% in-process control. Upstream, the pre-sterilized containers are manually to fully automatically unpacked and fed to the process. The post-processing section features such modules as backstop locks and safety devices, optical and sensor controls, labelers and track & trace systems. RAB systems and isolators can be deployed. A maximum output of 18,000 containers/hour is achieved via ten filling points, with a dosing range of 0.1 to 50 ml.

OPTIMA pharma GmbH
www.optima-pharma.com
E-mail: info@optima-pharma.com

 

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
8%
All of the above.
42%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here